Objectives: We aimed to determine the most common bacteria that cause urinary tract infections (UTIs), the rate of antibiotic resistance of these uropathogens, and the changes in resistance rates over the years for adult patients diagnosed with UTIs. Methods: We retrospectively reviewed urine cultures and antibiotic susceptibility results of patients >17 years of age from our outpatient clinic between 2014 and 2018. The most common uropathogens and their antibiotic resistance rates were identified in different age groups (18–39, 40–59, and ≥60 years) and with respect to gender and date of admission. In addition, the change in antibiotic resistance of Escherichia coli between 2014 and 2018 was also examined. Results: A total of 9,556 positive urine cultures were included. The most common uropathogen was E. coli, and its prevalence was higher in females than males (70.6 vs. 53.4%, respectively). The majority of isolates were from patients ≥60 years of age. E. coli resistance was most pronounced for ampicillin (61.56%), followed by trimeth-oprim-sulfamethoxazole (49.80%), amoxicillin-clavulanic acid (34.69%), and cefazolin (30.72%). E. coli resistance to ampicillin, nitrofurantoin, cefepime, ciprofloxacin, fosfomycin, and amoxicillin-clavulanic acid increased significantly with time (all p = 0.001). For E. coli, resistance to ciprofloxacin, one of the most commonly used antibiotics for UTI, increased from 17 to 43% from 2014 to 2018. Conclusion: Most of the uropathogens displayed high resistance to ampicillin, tri-methoprim-sulfamethoxazole, and amoxicillin-clavulanic acid, and were susceptible to meropenem, ertapenem, and imipenem. Fosfomycin and cefepime were useful in the empirical treatment of community-acquired UTIs. A surprisingly high increase was observed in the resistance of E. coli to antimicrobial agents from 2014 to 2018.

1.
Schaeffer
A
. Infections of the urinary tract. In: Campbell-Walsh Urology. 11th edn. Edited by Alan J. Wein LRK, Alan W. Partin, Craig A. Philadelphia, PA: Elsevier;
2016
. 237-303.e212.
2.
Tandogdu
Z
,
Wagenlehner
FM
.
Global epidemiology of urinary tract infections
.
Curr Opin Infect Dis
.
2016
Feb
;
29
(
1
):
73
9
.
[PubMed]
0951-7375
3.
Dellinger
RP
,
Levy
MM
,
Rhodes
A
,
Annane
D
,
Gerlach
H
,
Opal
SM
, et al.;
Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup
.
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012
.
Intensive Care Med
.
2013
Feb
;
39
(
2
):
165
228
.
[PubMed]
0342-4642
4.
Shepherd
AK
,
Pottinger
PS
.
Management of urinary tract infections in the era of increasing antimicrobial resistance
.
Med Clin North Am
.
2013
Jul
;
97
(
4
):
737
57
.
[PubMed]
0025-7125
5.
Wagenlehner
F
,
Tandogdu
Z
,
Bartoletti
R
,
Cai
T
,
Cek
M
,
Kulchavenya
E
, et al.
The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections
.
Pathogens
.
2016
Jan
;
5
(
1
):
E10
.
[PubMed]
2076-0817
6.
European Association of Urology (EAU)
.
Guidelines on urological infections
[http://uroweb.org/guideline/urologicalinfections/]
7.
CLSI
.
Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement
.
Wayne (PA)
:
Clinical and Laboratory Standards Institute
;
2013
., CLSI document M100-S23.
8.
Kranz
J
,
Schmidt
S
,
Lebert
C
,
Schneidewind
L
,
Mandraka
F
,
Kunze
M
, et al.
The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients: part 1
.
Urol Int
.
2018
;
100
(
3
):
263
70
.
[PubMed]
0042-1138
9.
Kranz
J
,
Schmidt
S
,
Lebert
C
,
Schneidewind
L
,
Mandraka
F
,
Kunze
M
, et al.
The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients: part 2: therapy and prevention
.
Urol Int
.
2018
;
100
(
3
):
271
8
.
[PubMed]
0042-1138
10.
Caretto
M
,
Giannini
A
,
Russo
E
,
Simoncini
T
.
Preventing urinary tract infections after menopause without antibiotics
.
Maturitas
.
2017
May
;
99
:
43
6
.
[PubMed]
0378-5122
11.
Knottnerus
BJ
,
Geerlings
SE
,
Moll van Charante
EP
,
ter Riet
G
.
Women with symptoms of uncomplicated urinary tract infection are often willing to delay antibiotic treatment: a prospective cohort study
.
BMC Fam Pract
.
2013
May
;
14
(
1
):
71
.
[PubMed]
1471-2296
12.
McIsaac
WJ
,
Moineddin
R
,
Gágyor
I
,
Mazzulli
T
.
External validation study of a clinical decision aid to reduce unnecessary antibiotic prescriptions in women with acute cystitis
.
BMC Fam Pract
.
2017
Oct
;
18
(
1
):
89
.
[PubMed]
1471-2296
13.
Gupta
K
,
Bhadelia
N
.
Management of urinary tract infections from multidrug-resistant organisms
.
Infect Dis Clin North Am
.
2014
Mar
;
28
(
1
):
49
59
.
[PubMed]
0891-5520
14.
Yang
B
,
Yang
F
,
Wang
S
,
Wang
Q
,
Liu
Z
,
Feng
W
, et al.
Analysis of the spectrum and antibiotic resistance of uropathogens in outpatients at a tertiary hospital
.
J Chemother
.
2018
May
;
30
(
3
):
145
9
.
[PubMed]
1120-009X
15.
Bader
MS
,
Loeb
M
,
Brooks
AA
.
An update on the management of urinary tract infections in the era of antimicrobial resistance
.
Postgrad Med
.
2017
Mar
;
129
(
2
):
242
58
.
[PubMed]
0032-5481
16.
Kandil
H
,
Cramp
E
,
Vaghela
T
.
Trends in Antibiotic Resistance in Urologic Practice
.
Eur Urol Focus
.
2016
Oct
;
2
(
4
):
363
73
.
[PubMed]
2405-4569
17.
Novelli
A
,
Rosi
E
. Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections. J Chemother.
2017
; 29(sup1):10-18.
18.
Oli
AN
,
Akabueze
VB
,
Ezeudu
CE
,
Eleje
GU
,
Ejiofor
OS
,
Ezebialu
IU
, et al.
Bacteriology and Antibiogram of Urinary Tract Infection Among Female Patients in a Tertiary Health Facility in South Eastern Nigeria
.
Open Microbiol J
.
2017
Oct
;
11
(
1
):
292
300
.
[PubMed]
1874-2858
19.
Yılmaz
N
,
Ağuş
N
,
Bayram
A
,
Şamlıoğlu
P
,
Şirin
MC
,
Derici
YK
, et al.
Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008-2014)
.
Turk J Urol
.
2016
Mar
;
42
(
1
):
32
6
.
[PubMed]
2149-3235
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.